SSRI antidepressant use patterns and their relation to clinical global impression scores: A naturalistic study

Journal of Affective Disorders

Volumn 52, Issue 1-3, 1999, Pages 111-119

  Hylan, Timothy R ^a,b   Meneades, Laurie ^c   Crown, William H ^c   Sacristan, Jose A ^d   Gilaberte, Inma ^d   Montejo, Al ^e  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c MEDSTAT GROUP   (United States)

^d DCRandT   (Spain)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Antidepressants; CGI scale; Selective serotonin reuptake inhibitors

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; AGE; ARTICLE; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM;

ADULT; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0032924026     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(98)00064-0     Document Type: Article

References (38)

1. Anderson I.M., Tomenson B.M. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J. Psychopharmacol. 8(4):1994;238-249.
2. Bingefors K., Isacson D., von Knorring L. Antidepressant dose patterns in Swedish clinical practice. International Clinical Psychopharmacology. 12:1997;283-290.
3. Bourgeois, 1996. Review of clinical use of sertraline by family practice physicians in a small Air Force hospital. Mil. Med. 161(7): 425-7.
4. Cox D.R. Regression models and life tables (with discussion). J. R. Stat. Soc. B34:1972;187-220.
5. Croghan T., Lair T.J., Engelhart L.E.et al. Effect of antidepressant therapy on health care utilization and costs in primary care. Psychiatr. Serv. 48(11):1997;1420-1426.
6. Donoghue J.M. Prescribing patterns of selective serotonin reuptake inhibotors in primary care: a naturalistic follow-up study. J. Serotonin Res. 4:1996;267-270.
7. Donoghue J.M., Tylee A., Wildgust H. Cross-sectional database analysis of antidepressant prescribing in general practice in the United Kingdom. Br. Med. J. 313:1996;811-812.
8. Ekselius L., von Knorring L., Eberhard G. A double-blind study comparing sertraline and citalopram in patients with major depression treated in general practice. Eur. Neuropsychopharmacol. 7(2):1997;S147.
9. Greene, W.H., 1995. Econometric Analysis. Macmillan, New York.
10. Gregor K., Overhage J.M., Coon S.J., MacDonald R.M. Selective serotonin reuptake inhibitor dose titration in a naturalistic setting. Clin. Ther. 16(2):1994;306-315.
11. Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare publication ADM 76-338. National Institute of Mental Health, Rockville MD, pp. 217-222.
12. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 23:1960;56-62.
13. Haynes R.B., Dantes R. Patient compliance and the conduct and interpretation of therapeutic trials. Control. Clin. Trials. 8(1):1987;9-12.
14. Haynes, R.B., Sackett, D.L., Taylor, D.W., 1978. Practical management of low compliance with antihypertensive therapy: a guide for the busy practitioner. Clin. Inv. Med., 1(3-4): 175-80.
15. Hylan TR (1997) Antidepressant use in clinical practice. J. R. Soc. Med. (Supplement); in press.
16. Hylan T.R., Crown W.H., Meneades L., Melfi C., Croghan T.W., Buesching D.P. SSRI and TCA antidepressant selection and health care costs: a multivariate analyses. J. Affect. Disord. 47(1):1998;71-79.
17. Johnson D. Non-compliance with antidepressant therapy: an underestimated problem. Journal of Internal Medicine. 11:1986;14-17.
18. Katon W., Von Korff M., Lin E., Bush T., Ormel J. Adequacy and duration of antidepressant treatment in primary care. Med. Care. 30(1):1992;67-76.
19. Kasper S., Fuger J., Moller H.J. Comparative efficacy of antidepressants. Drugs. 43:1992;11-22.
20. Katzelnick D., Kobak K.A., Jefferson J., Greist J.H., Henk H.A. Prescribing patterns of antidepressant medications for depression in an HMO. Formulary. 31:1996;374-388.
21. Maj M., Veltro F., Pirozzi R., Lobrace S., Magliano L. Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am. J. Psychiatry. 149(6):1992;795-800.
22. McCombs J.S., Nichol M.B., Stimmel G.L., Sclar D.A., Beasley C.M., Gross L.S. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J. Clin. Psychiatry. 51:1990;60-69.
23. McCombs, J.S., Nichol, M.B., Stimmel, G.L., 1997. The role of SSRI antidepressants for treating depressed patients in the California Medicaid (Medi-Cal) program. Int. Clin. Psychopharmacol., in press.
24. Mintz J., Mintz L.I., Arruda M.J., Hwang S.S. Treatments of depression and the functional capacity to work. Arch. Gen. Psychiatry. 49(10):1992;761-768.
25. Montgomery S.A. Prophylaxis in recurrent unipolar depression: a new indication for treatment studies. J. Psychopharmacol. 3:1989;47-53.
26. Navarro, R., Valler, W.E., Spangle, M., 1995. Antidepressant utilization in managed care: an evaluation of SSRI use in two HMO settings. Med. Interface, 8(8): 114-119, 123.
27. Obenchain R.L., Melfi C.A., Croghan T.W., Buesching D.P. Bootstrap analyses of cost-effectiveness in antidepressant pharmacotherapy. Pharmacoeconomics. 11:1997;464-472.
28. Olufade, A.O., James, S., Gregor, K.J., 1997. Efficacy vs. effectiveness: the generalizability of randomized controlled trials in depression. Data on file, PCS Health Systems.
29. Paykel E.S., Priest R.G. Recognition and management of depression in general practice. Br. Med. J. 205:1992;1198-1202.
30. Potter W.Z., Rudorfer M.V., Monji H. The pharmacologic treatment of depression. New Engl. J. Med. 325:1991;633-642.
31. Prien R.F., Kupfer D.J. Continuation drug therapy for major depressive disorder: how long should it be maintained? Am. J. Psychiatry. 143:1986;18-23.
32. Quitkin F.M., McGrath P., Stewart J.W.et al. Chronological milestones to guide drug change. When should clinicians switch antidepressants? Arch. Gen. Psychiatry. 53:1996;785-792.
33. Sclar D.A., Robison L.M., Skaer T.et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization. J. Int. Med. Res. 23:1995;395-412.
34. Simon G.E., Von Korff M., Wagner E.H., Barlow W. Patterns of antidepressant use in community practice. Gen. Hosp. Psychiatry. 15(6):1993;399-408.
35. Sturm R., Wells K. How can care for depression become more cost-effective? J. Am. Med. Assoc. 273(1):1995;51-58.
36. Thompson D., Buesching D., Gregor K., Oster G. Patterns of antidepressant use and their relations to costs of care. Am. J. Managed Care. 2(9):1996;1239-1246.
37. Wernicke J.F., Bosomworth J.C., Ashbrook E. Fluoxetine at 20 mg per day: the recommended and therapeutic dose in the treatment of depression. Int. Clin. Psychopharmacol. 4(Suppl 1):1989;63-67.
38. World Health Organization Mental Health Collaborating Centers, 1989. Pharmacotherapy of depressive disorders: WHO consensus statement. J. Affect. Disord., 17, 197-198.